

Financial Disclosure


- I have the following financial relationships to disclose:
 - Grants / Research & Clinical Study Support : WL Gore
 - Non-compensated Advisory Boards: Intact Vascular & Intressa (formerly Cardiatis)


MFM DEVICES ? What is an MFM Device


 Multiple variations of porous self-expanding endografts

- no standardized characterization

- Theoretical mechanisms proposed and validated with computerized flow models
- Been evaluated in multiple clinical applications









MFM DEVICES

- Animal evaluations
 - rapid incorporation of stent matrix when opposed to vessel wall
- side branch patency maintained up to 1 yr






MFM DEVICES

- Cerebral Devices (multiple MFM devices that have been proven effective to treat cerebral aneurysms)
 - -Balt Silk +
 - Pipeline
 - Surpass
 - Fred
 - Casper
 - Intressa (formerly) Cardiatis

MFM Devices for Visceral & Peripheral Arteries

 Several reports of clinical studies
mixed results with limited reports, mostly small patient series



Endovascular repair of peripheral and visceral aneurysms with the Cardiatis multilayer flow modulator: one-year results from the Italian Multicenter Registry

Maria Antonella Ruffino ¹, Claudio Rabbia; Italian Cardiatis Registry Investigators Group

Collaborators, Affiliations PMID: 23046324 DOI: 10.1583/JEVT-12-3930MR2.1

Abstract

Purpose: To assess the efficacy of the Cardiatis multilayer flow modulator (CMFM), a bare cobalt alloy self-expanding stent, in the treatment of peripheral and visceral artery aneurysms.

Methods: In this multicenter (n=22), prospective, voluntary registry, <u>54 patients</u> (47 mer, mean age 68 years, range 13-87) who underwent CMFM deployment for <u>peripheral</u> (n=35) or visceral aneurysms (n=15) in a varied of target arteries were enrolled between June 2006 and June 2010. Among the 54 lesions, 44 had a total of 53 side branches. The main effectiveness endpoint was stent and side branch patency with no aneurysm rupture or reperfusion at 1, 6, and 12 months after stent implantation. Outcome measures were complete neurysm thrombosis and sac shrinkage. The safety endpoint was stent with same stent and stent stent implantation. Methods: In this multicenter (n=22), prospective, voluntary registry, 54 patients (47 men; mean age 68 years, range 19-87) who underwent CMFM deployment for peripheral (n=35) or visceral aneuryms (n=19) in a variety of target arteries were enclide between Anne 2009 and June 2010. Among the 54 lesions, 44 had a total of 53 side branches. The main effectiveness endpoint was steent and side branch patency with no aneuryms nupture or enclide batween Alars 2009 and tares stent implantation. Outcome measures were complete aneuryms thrombosis and sace stimkarge. The safety endpoint was freedom of complications (death, aneuryms nupture, endoelak, need for reintervention, stent foreshortening, stent occlusion, and access-site sequelae). Aneuryms were categorized as saccular (type I) or fusiform (type II) without a side branch or with branch(es) in the sac (subtype A), neck (subtype A), or both (subtype A), Kaplan-Meier estimates were calculated for primary and secondary endpoints. Sac stimkage was correlated to aneuryms morphology subtypes and presency/absence of musil thrombus.

Results: Technical success was achieved in all patients. Mortality at 1 year was 5.5% (n=3), including 1 perioperative death. Six patients were lost to follow-up. There was no aneurysm rupture. <u>54x</u> (11.1%) stents occluded over the 1-year period: 3 asymptomatic patients were not treated. 2 symptomatic patients had successful stent dilation to restore patiency, and 1 symptomatic patient required bypass (the only side branch lost). Cumulative primary and secondary patency estimates were 86.9% and <u>90.7%</u> at 1 year. The cumulative side branch patency was <u>96.1%</u> and the freedom from all complications was <u>83.0%</u> at 1 year. Complete aneurysm thrombosis was recorded in 42 (93.3%) of 45 patients at 1 year. Percent diameter reduction was <u>15%</u>, <u>38%</u>, and <u>110%</u> at 1.6, and <u>120</u> months (#0.000), negoettively. Presence of mural thrombus dd not influence the time course of shinkage on <u>0.000</u>, while negalabulism examples means and <u>info</u> handles <u>100</u> or <u>0.000</u>.

(p>0.05), while complex lesion anatomy (presence of side branches) delayed shrinkage (p<0.05). Conclusion: Results at 1 year show that CMFM can be safely used in the treatment of PAA and VAA,

with good results in terms of freedom from rupture, patency of the stents and side branches, complete aneurysm thrombosis, shrinkage, and acceptable freedom from morbidity and mortality.

iew Ther Adv Cardiovasc Dis. 2024 Jan-Dec:18:17539447241283736.

doi: 10.1177/17539447241283736.

Role of multilayer flow modulator stents in the treatment of arterial aneurysms

Rasit Dinc¹, Evren Ekingen

Affiliations PMID: 39418136 PMCID: PMC11489923 DOI: 10.1177/17539447241283736

Abstract

Arterial aneurysms remain a significant public health problem because they often result in death when ruptured, therefore, they require immediate medical treatment. Endovascular aneurysm repair (EVAR) has recently become the primary treatment option, owing to the fevere side fefects compared to those with open surgery. However, stents used for conventional EVAR often cause side-branch occlusion, which alters the perfusion of vital organs. Recently, multilayer flow modulator (MFM) stents have been used as a new treatment for arterial aneurysms. These stents appear to be feasible owing to their unique design consisting of an uncoated three-dimensionally braided multilayered structure. MFM stents generally remodulate laminar flow and reduce the flow velocity in the aneurysmal sixe, leading to thrombosis, which causes the aneurysm to shrink over time. Thus, they reduce the risk of mortality.

Multicenter Study Vascular. 2018 Oct;26(5):556-563. doi: 10.1177/1708538118771258.

Early and mid-term results in the endovascular treatment of popliteal aneurysms with the multilayer flow modulator

Alessandro Ucci ¹, Ruggiero Curci ², Matteo Azzarone ¹, Claudio Bianchini Massoni ¹, Antonio Bozzani ³, Carla Marcato ⁴, Enrico Maria Marone ³, Paolo Perini ¹, Tiziano Tecchio ¹, Antonio Freyrie ¹, Angelo Argenteri ³

Affiliations PMID: 29665749 DOI: 10.1177/1708538118771258

Abstract

Background The endowscular approach became an alternative to open surgical treatment of popiliteal artery neurysm over the last few years. Heparini-bonded stent-grafts have been employed for endowscular popiliteal artery aneurysm repair, showing good and stable results. Only few reports about the use of multilayer flow modulator are available in literature, providing small patient series and short follow-up. The aim of this study is to report the outcomes of patients with popiliteal artery aneurysm treated with the multilayer flow modulator in three tailain centers. Methods We retorspectively analysed a series of both symptomatic and asymptomatic patients with popiliteal artery aneurysm treated with the multilayer flow modulator in three tails in centers. Methods We retorspectively analysed a series of both symptomatic and asymptomatic patients with popiliteal artery aneurysm treated with the symptomatic and asymptomatic patients with popiliteal artery aneurysm treated with the symptomatic and asymptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popiliteal artery aneurysm treated with the symptomatic patients with popili

Case Reports Vasa. 2012 Sep;41(5):383-7. doi: 10.1024/0301-1526/a00022

Multilayer stent in the treatment of popliteal artery aneurysms

George A Antoniou¹, Andrew Schiro, J Vincent Smyth, David Murray, Finn Farquharson, Ferdinand Serracino-Inglott

Affiliations


Affiliations PMID: 22915538 DOI: 10.1024/0301-1526/a000227


Abstract


Endovascular repair of popliteal artery aneurysms is an emerging treatment in high risk surgical patients. The location in a functionally demanding anatomical area creates limitations in terms of endograft patienty. Technological advancements have been conscripted in an effort to circumvent such constraints. The multilayer stent technology effects through haemodynamic modulation. We used the multilayer stent to tread 6 asymptomatic popliteal artery neurysms in 3 patients. All procedures were successfully accomplished without any complications. Over a mean follow up périod of 9 months. thrombosis occurred in two limbs, and blood flow was restored with thrombolysis, achieving a primary and secondary patency rate at 6 months of 67 % and 100%, respectively. Partal or complete thrombosis of the aneurysm sac was achieved in all aneurysms. Even though the use of the multilayer stent in popliteal artery aneurysms was safe in the short term, our experience showed that close surveillance is required.

Abstract


Background The endovascular approach became an alternative to open surgical treatment of popliteal attery aneurysm over the last few years. Heparin-bonded stent-grafts have been employed for endovascular popliteal attery aneurysm repair. Showing good and stable results. Only few reports about the use of multilayer flow modulator are available in literature, providing small patient series and hort follow-up. The aim of this tudy is to report the outcomes of patients with popliteal attery aneurysm treated with the multilayer flow modulator in three talian centres. Methods We retrospectively analysed a series of both symptomatic and anymptomatic patients with popliteal attery aneurysm treated with the multilayer flow modulator from 2009 to 2015. Follow-up was undertaken with fulcial and contrast-enhanced ultrasonal esaminations at 1.6 and 12 months, and yarly thereafter. Computed tomography angiography was performed in selected cases. Primary endpoints were aneurysm tact thombosis; freedom from sac enlargement and primary assisted and secondary patency during follow up. Secondary endpoints were technical success, collateral vessels patency, limb salvage and aneurysm-related complications. Results Twenty-three consecutive patients (19 males, age 21 ± 11) with 25 popliteal attery aneurysm. Instand interer 23 mm ± 1, 3 symptomatic patients; were treated with 40 multilayer flow modulators during the period of the study. Metain follow-up. Secondary adhoptive three was 55.7%, 07.5% and 70.1%, respectively. At 16, bit a and 24 months, estimated primary patiency was 55.7%, 07.5% and 70.0%, respectively. At 16, bit a and 24 months, 95.7%, 93.9%, and 90.3%, 91.4% at 42-month follow-up. One multilayer flow modulator facture was reported in an asymptomatic patient. Conclusions with Withinger flow modulator sensible and sales solution for endovascular treatment of popliteal attery aneurysm is selected patients.





















Systematic Review and Patient-Level Meta-analysis of the Streamliner Multilayer Flow Modulator in the Management of Complex Thoracoabdominal Aortic Pathology

Niamh Hynes, MRCS, MMSc, MD^{1,2*}, Sherif Sultan, MCh, MD, FRCS, PhD^{1,2*}, Ala Elhelali, MSc^{1,3}, Edward B. Diethrich, MD⁴, Edel P. Kavanagh, PhD¹, Mohamed Sultan, BSc¹, Florian Stefanov, PhD^{1,3}, Patrick Delassus, PhD³, and Liam Morris. PhD³

Results: Fifteen articles (3 multicenter cohort studies, 3 observational cohort studies, and 9 case reports) were included, presenting 71 patients (mean age 68.8±12.3 years; 139 men). The mean aneurysm diameter was 6.7±1.6 cm (95% CI 6.4 to 6.9 cm). Technical uccess reported in 15 studies was 77.2%. Aneurysm-related survival at 1 year was 78.7% (95% CI 71.7% to 94.4%). One-year allause survival was 53.7% (95% CI 46.0% to 13%). There were no reported cases of spinal cord ischemia, renal insult, or stroke. Conclusione, The SMFM can be safely utilized in some patients with complex thoracoabdominal pathologies provided operators adhere to the IFU. The SMFM is a novel technology with no long-term published data on its sustained effectiveness low-modulating technology can be widely disseminated. Multilayer Flow Modulator Treatment of Abdominal and Thoracoabdominal Aortic Aneurysms With Side Branch Coverage: Outcomes From a Prospective Single-Center Moroccan Registry Amira Benjelloun, MD¹, Michel Henry, MD², Mustapha Taberkant, MD³, Abdelaziz Berrado, PhD¹, Michel Henry, MD², Mustapha Taberkant, MD³, Abdelazis Berrado, PhD¹, Kachid El Houati, MD¹, and Abdelkader Semiali, MD⁴ Purpose: To evaluate endoacular repair of thoracobonnial aortic aneuryms (TAAA) and abdominal aortic aneuryms AAA) using the Multilayer Flow Modulator (MPJ) in high-unglaci-like planes with at least one covered banch vessel. Yeehods: In this prospective single-center nonandonized trial. IB patients with a least one covered banch vessel. Yeehods: In this prospective single-center nonandonized trial. IB patients with a least one covered banch vessel. Yeehods: In this prospective single-center nonandonized rail. IB patients with a least one covered banch vessel. Yeehods: In this prospective single-center nonandonized trial. IB patients with a least one covered banch vessel. Yeehods: In this prospective single-center nonandonized trial. IB patients (mean age 611) years: IG meny with TAAA rel10, mean diameter 74.4 mm) and AA (res. R. man dimeter 63.8 mm) were reated with the MPM between June 2009 ind spettember 2012. The primary steley endpoints were all-cause mortality at 30 dys and 12 months and neurological pomplications. The man stretted least 73.7 mm.] Through mean follow-up of 14 months, all Covered banch vessels remained patent; there were no neurologic complications, rupture, or instance of device migration, linking, or fracture. Three patients dial covered months were allocause and one of an undetermined cause. Only one reintervention with an additional TPM implated at 5 years was required for a type 1 endolek in a young patient with natural growth. Carefully planned in devecuted dimeter and volume measurements. Canedication, undetervented cause, other devectore graviton, kinking, or fracture thow have and the

MFM for TAA

- Initial IFU from Cardiatis described limit TAA size to 6 cm
- -contraindicated for ruptures or infection
- Multiple studies have evaluated device for TAAs with mixed results
- Current protocols focused on MFM for dissections where results are very promising
- Current data supports that Intressa is effective for cerebral aneurysms and dissections
- TAA indication yet to be determined



Intressa In Clinical Practice

- "Disruptive" technology with need for studies that clearly documents continued patency and delineates the requirement for predilation of arterial lesions to preserve patency
 - appears to be similar to current indications predilation of branch vessels for fenestrated

Role of MFM in Clinical Practice

- Large diameter applications less well documented "Tubular" large vessel lesions ie., IMH, penetrating ulcers, dissections Aneurysm studies have not convincing (limited long-term follow-up in registry studies, with aneurysm stabilization but increasing diameter in large aneurysms, or associated with endoleaks Many reports of failure were contraindications infection, ruptures, or outside the IFU,ie., land in normal artery both ends, overlap long and oversized, etc

